Array Biopharma (ARRY) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.22 +11.05%
Revenue Growth %: -18.0%
Financial Fact:
Cost of revenue: 8.85M
Today's EPS Names:
INM, TRI, CRVL, More
Revenue Growth %: -18.0%
Financial Fact:
Cost of revenue: 8.85M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.17), $0.11 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $35.4 million versus the consensus estimate of $32.7 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Citi expects ’continued memory undersupply’ in 2027
- Chegg (CHGG) Misses Q3 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
